Home » Whistle-Blower Complaint Delayed Approval of Savella
Whistle-Blower Complaint Delayed Approval of Savella
Allegations from a whistle-blower regarding the integrity of the clinical study data supporting Forest Laboratories’ NDA for fibromyalgia drug Savella delayed agency approval of the product for nearly three months. The resulting for-cause inspection in December was successful, and the drug was approved Jan. 14 under a REMS program that requires a MedGuide.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May